Physician profile
David A Bigler
NPI 1740398320
$7,406.79
in general payments reported to CMS, 2019-2025
27 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 75% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $766 · 2021: $1,137 · 2022: $1,137 · 2023: $1,321 · 2024: $1,082 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908 · Education: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,908.09 |
| Education | $546.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,950.01 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $821.59 | 2019-2025 | Ilumya |
| Genzyme Corporation | $775.80 | 2021-2025 | |
| Janssen Biotech, INC. | $712.36 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $639.73 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $519.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $459.63 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $257.71 | 2023-2025 | Sotyktu |
| Amgen INC. | $244.03 | 2019-2024 | Otezla |
| Ucb, INC. | $194.56 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $136.73 | 2019-2023 | Arazlo, Jublia |
| Leo Pharma INC. | $115.37 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $89.47 | 2019-2025 | Aklief, Nemluvio |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Dermira, INC. | $67.79 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.23 | 2019-2025 | |
| Dusa Pharmaceuticals, INC. | $53.81 | 2019 | |
| Celgene Corporation | $52.78 | 2019 | |
| Genentech USA, INC. | $25.77 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $23.62 | 2020 | |
| Arcutis Biotherapeutics, INC. | $23.41 | 2025 | Zoryve |
| Convatec INC. | $20.69 | 2025 | |
| Organon LLC | $16.66 | 2025 | Vtama |
| Dermavant Sciences, INC. | $16.46 | 2024 | Vtama |
| Almirall LLC | $15.21 | 2025 | Klisyri |
| Allergan, INC. | $14.66 | 2019 | |
| Promius Pharma LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bigler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.